Sunshine Guojian Pharmaceutical Shanghai
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors.
Launch date
Employees
Market cap
$1.5b
Enterprise valuation
$1.4b (Public information from Sep 2024)
Share price
CNY18.31 688336.SS
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 655m | 929m | 825m | 1.0b | 1.3b | 1.3b | 1.5b |
| % growth | (44 %) | 42 % | (11 %) | 23 % | 25 % | 6 % | 14 % |
| EBITDA | (97.3m) | 52.2m | 127m | 324m | 342m | 394m | 433m |
| % EBITDA margin | (15 %) | 6 % | 15 % | 32 % | 27 % | 30 % | 28 % |
| Profit | (217m) | 18.1m | 49.3m | 295m | 320m | 281m | 331m |
| % profit margin | (33 %) | 2 % | 6 % | 29 % | 25 % | 21 % | 22 % |
| EV / revenue | 23.2x | 12.3x | 9.5x | 13.7x | 8.3x | 7.8x | 6.8x |
| EV / EBITDA | -156.1x | 219.2x | 61.5x | 42.8x | 30.5x | 26.5x | 24.1x |
| R&D budget | 340m | 455m | 313m | 282m | - | - | - |
| R&D % of revenue | 52 % | 49 % | 38 % | 28 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Sunshine Guojian Pharmaceutical Shanghai
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
